AIDACAnti-Infective Drugs Advisory Committee
References in periodicals archive ?
Flavin continued, "We remain encouraged by the supportive comments made by AIDAC committee members in June relative to their positive view of the safety profile of Restanza, the therapeutic need for more effective treatments for CAP and their interest in seeing the company pursue further development.
We will work towards achieving a label that accurately reflects the data from the company's landmark trial, the patient population studied, as well as the guidance to the FDA from the AIDAC, which met less than three weeks ago.